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Abstract 
 
 Obesity has reached epidemic proportions in most of the Westernized world. Overweightness 
and obesity adversely impact cardiac structure and function, including on both the right and , especially,  
left sides of the heart, with adverse affects on systolic and, especially,  diastolic ventricular function. 
Therefore, it is not surprising that obesity  makedly increases the prevalence of heart failure (HF).  
Nevertheless, many studies have documented an obesity paradox in large cohorts with HF, where 
overweight and obese have a better prognosis, at least in the short-term, compared with lean HF 
patients.  Although weight loss clearly improves cardiac structure and function and reduces symptoms in 
HF, there are no large studies on the impact of weight loss on clinical events in HF, preventing definitive 
guidelines on optimal body composition in patients with HF.   
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Abbreviations 
 
% BF = Percent Body fat 
BMI = Body mass index 
BP = Blood pressure 
CHD = Coronary heart disease 
CO = Cardiac output 
CRF = Cardiorespiratory fitness 
CV = Cardiovascular  
CVD = Cardiovascular disease  
HF = Heart failure 
HTN = Hypertension 
LA          =     Left atrium or atrial  
LV = Left ventricular  
LVH = Left ventricular hypertrophy 
LVM = Left ventricular mass 
RV =  Right ventricle 
VO2 = oxygen consumption 
WC  = Waist circumference 
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 Overweight and obesity are generally defined by body mass index (BMI) criteria, which is useful 
in large population studies, but flawed in individual patients, since BMI reflects both fat mass and non-
fat mass ( mostly muscle and skeletal mass), leading to suggestions that alternative methods to define 
obesity, including waist circumference (WC) , waist-to-hip-ratio, and percent body fat (% BF) may better 
reflect at risk body fatness. 1-3   Obesity is certainly a major risk factor for most cardiovascular (CV) 
diseases (CVD), including for hypertension (HTN) and coronary heart disease (CHD), two of the major risk 
factors for the development of heart failure (HF).1,4-6  Additionally, obesity has more direct effects on the 
pathogenesis of HF, due to its negative impact on cardiac morphology and performance, including 
negative impact on both systolic and, especially, diastolic left ventricular  (LV) function.5,6,7,8  Therefore, 
it is of no surprise that HF is dramatically increased in the setting of obesity.   
 
 However, despite the adverse effects that obesity has on CVD risk factors and its association 
with increased incidence of most CVD, including HTN and CHD, (both of which are strongly related with 
the increased risk of HF), and for HF itself, many large studies have demonstrated the powerful "obesity 
paradox" in cohorts with established HF.  In fact,  the presence of overweight and obese , at least mild 
obesity in those with HF , appears to confer a better short- and intermediate-term prognosis than in 
their leaner counterparts who  have similar degrees of HF.5,6,9 
 
 In this review, we describe the adverse effects of overweight/obesity on hemodynamics, as well 
as on cardiac structure and ventricular function.  The impact of obesity on HF prevalence is reviewed, as 
well as studies showing an obesity paradox in HF.  Finally, we discuss the role of fitness and weight loss 
in obese patients with HF, as well as the need for more studies on this topic. 
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Impact of Obesity on  Cardiac Morphology and Performance 
 
 Alpert and colleagues7,8 have recently reviewed this topic in detail.  Considerable evidence 
underscores the adverse effects of excessive adipose accumulation and associated fat-free mass on 
central and peripheral hemodynamics, as well as on cardiac structure and systolic and diastolic LV 
function (Figure 1, Table 1).5,7   
 
Hemodynamics.  There are many hemodynamic alterations in obesity, leading to increased total 
and central blood volume and increased stroke volume and cardiac output (CO).5,7,8  Typically, obesity 
leads to a reduction in systemic vascular resistance in normotensive obese persons, which facilitates the 
increase in CO despite the fact that heart rate is not substantially impacted in obesity.  Arteriovenous 
oxygen differences are usually widened in obesity, due to lower oxygen extraction by adipose tissue.  
Thus, blood flow per unit of weight is reduced, especially in more severe degrees of obesity and in 
combined obesity/HTN, where systemic vascular resistance is also increased. 5,7,8   
 
In Class II and III obesity, increased venous return leads to increased preload with increased LV 
filling pressure.  This further contributes to elevated pulmonary artery and right heart pressures.5,7,8  
With exercise in Class III obesity, central blood volume  increased by 20%, LV end-diastolic pressure 
increased by 50%, and the LV dP/dt increased by 57%. 5,10   
 
Cardiac Structure.  Obesity also produces marked abnormalities in cardiac structure, including 
LV hypertrophy (LVH),5,7,8,11 as well as enlargement of the atria and right side of the heart.  Although LV 
mass (LVM) is commonly increased in obesity,5,7,8,11,12 blood pressure (BP) seems to be an important 
component of such augmentation.  Additionally, LVM markedly increases progressively with the severity 
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of obesity.  Based on the hemodynamic alterations discussed previously, it seems logical that the 
elevated blood volume and CO would lead to LV dilatation and more eccentric LVH.  However, several 
studies suggest that in Class I and II obesity, the incidence of concentric remodeling and concentric LVH 
may exceed the incidence of eccentric LVH.5.7,8  However, without elevated BP, eccentric LVH may be 
more prevalent.  Obviously, studies that assess the impact of obesity on LV geometry should account for 
obesity severity and levels of BP, as well as duration of obesity.5,7,8 
 
Ventricular Function.  Obesity also has adverse effects on ventricular function.5,7,8,11,12  Most 
studies assessing LV systolic function in obese patients using LV ejection phase indices have reported 
normal or even hyperdynamic LV function.  Even in severe obesity, LV systolic dysfunction is relatively 
uncommon in the absence of coexisting CVD.  In severe obesity, however, the presence of severe LVH 
causes blunting of the exercise induced rise in LV systolic function.  Additionally, studies using tissue 
Doppler imaging have reported subclinical LV systolic dysfunction in obesity that is thought to be load 
independent, suggesting the presence of intrinsic abnormalities of LV contraction.5,7,8,11,12  
 
More importantly, however, studies demonstrate impaired LV diastolic function in obese 
patients, especially in combination with LVH.5,7,8  Nevertheless, some studies have reported diastolic LV 
dysfunction independent of LVM.  Although LV diastolic dysfunction has been reported for many years 
with several imaging techniques,5,7,8,12,13 more recent studies with tissue Doppler have particularly 
identified LV diastolic dysfunction as a subclinical disorder in obesity. The prevalence of LV diastolic 
dysfunction increases with increases of severity of obesity, from 12% of Class I, 35 % of Class II, and 45 % 
of Class III obese patients in one study. 14  Most studies demonstrating impaired LV diastolic function in 
obesity have reported a high prevalence of LVH, with progressive impairment of LV diastolic function 
with increasing LVM ( presumably due to muscle, fibrosis and intra-myocardial fat.) 5,7.8  
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Additionally, obesity has adverse affects on the left atrium (LA) and right ventricle (RV), and particularly 
abnormalities are noted with the common combination of obesity, HTN, and LVH.5,7,8,12,13,15Recent 
studies have reported  abnormal LA strain in obesity, particularly in those with more LA enlargement 
and coexisting HTN. 7,16  RV function has not been as extensively studied in obesity, partly due to 
difficulties with older imaging techniques in obese patients, but studies employing tissue Doppler 
imaging show reduced systolic and diastolic  velocities of the lateral tricuspid valve annulus and reduced 
RV strain.7 
 
 
Obesity and HF 
 
Considering the adverse effects of adiposity on hemodynamics and LV structure and ventricular 
function, not surprisingly, obesity leads to marked increases in the prevalence of HF.5,6  Additionally, 
myocardial lipotoxicity and lipoapoptosis has also been described with severe obesity in animal models 
and may potentially contribute to an obesity cardiomyopathy in humans; however, other factors, 
including increased activation of the renin-angiotensin-aldosterone system, increased sympathetic tone, 
insulin resistance, and hyperleptinemia are likely much more important .7, 8 Although a detailed 
discussion of the pathophysiology related with leptin in the development of CVD and HF is beyond the 
scope of this review and is briefly reviewed elsewhere, 1 leptin is involved with increasing BP  and the 
development of HTN, as well as leading to vascular and myocardial injury, that may be important in the 
pathogenesis of  HF. 
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The largest study to assess the risk of HF in obesity is derived from the Framingham Heart 
Study.17  In a study of 5,881 participants, Kenchaiah and colleagues17 demonstrated a marked increase in 
the prevalence of HF in both men and women.  In fact, for every 1 kg/m2 increase in BMI, the risk of HF 
increased by 7% in women and 5% in men, with graded increases in HF prevalence across all BMI 
categories (Figure 2).17  Alpert and colleagues18 have reported that HF is also strongly impacted by 
obesity severity and duration of obesity.  In a study of 74 morbidly obese patients, nearly ⅓ had clinical 
evidence of HF, and the probability of  HF increased substantially with increasing duration of morbid 
obesity, with prevalence rates exceeding 70% at 20 years and 90% at 30 years.18  
 
Obesity Paradox in HF 
 
Despite the adverse affects of obesity on LV structure and function that markedly increases the 
prevalence of HF in obesity, numerous studies have now reported a powerful relationship between 
obesity and  prognosis, with overweight and, especially, obese Class I and II  HF patients having the 
better prognosis than do their leaner counterparts with HF.5,6  Horwich and colleagues19 first described 
this almost 15 yeas ago, and this association  has now been confirmed in many studies and meta-
analyses.  Sharma and colleagues20 recently reported a meta-analysis of 6 studies (N=22,807) that 
assessed adverse events, including CV mortality, all-cause mortality, and rehospitalizations, during a 2.9 
year mean follow-up (Figure 3);20   prognosis was the worst with low BMI, whereas the lowest risk 
occurred in the overweight  Another  study of 6,142 patients with acutely decompensated HF from 12 
prospective studies from 4 continents also confirmed an obesity paradox,  mostly confined to older 
persons, those with reduced cardiac function, less cardiometabolic illness, and recent onset HF.21  A 
study from the Cleveland Clinic of 3,811 patients with systolic HF showed that the survival paradox of 
high BMI disappeared in males after adjustments for potential confounders( age, race, HF etiology,  New 
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York Heart Association classification, drug therapy, and exercise performance), with overweight and 
obese males showing higher adjusted mortality hazard ratios compared to normal weight males.9,22  On 
the other hand, overweight female patients had a significant 16% lower mortality with a nadir in 
mortality hazard just below the cutpoint of 30 kg/m2.  The multivariate model also supported a 
differential impact of BMI on mortality in males vs. females.  Although other studies have indicated an 
obesity paradox in HF independent of gender,9 this recent analysis had substantial information on 
potential confounders that were not present in at least some of the other studies.   
 
Additionally, most of the studies assessing the obesity paradox in HF have only used BMI and 
not measured other variables of body composition and obesity, such as % BF or WC.  However in a study 
of 209 patients with advanced systolic HF, Lavie et al23 demonstrated an obesity paradox with both BMI 
and  % BF.  In fact, for every 1% increase in % BF, there was a 13% independent reduction in major CV 
events.  A recent study from Clark et al24,25   demonstrated that both higher BMI and higher WC were 
associated with better event-free survival in HF, with the best survival being noted in those with both 
high BMI and high WC.6,24,25   
 
Mechanisms for the Obesity Paradox in HF 
 
The mechanisms for the obesity paradox in CVD and HF particularly remain somewhat unclear 
and difficult to reconcile, but several potential reasons are listed in Table 2.5  Certainly, advanced HF is a 
catabolic state, and heavier HF patients may have more metabolic reserve, whereas frail and cachectic 
patients (discussed later) experience greater morbidity and mortality for many diseases, including HF.  
Adipose tissue is also known to promote soluble tumor necrosis factor-alpha receptors that could be 
protective in patients with greater adiposity by neutralizing tumor necrosis factor.  Additionally, 
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overweight and obese HF patients have reduced expression of circulating natriuretic peptides,5,26 which 
could lead obese HF patients to become symptomatic with edema and dyspnea and present earlier with 
excess volume accumulation occurring at less severe stages of HF, which could lead to earlier treatment 
with cardioprotective medications.  Because obesity is usually associated with greater blood volume and 
BP, obese patients with HF should be able to tolerate higher doses of various cardioprotective CV 
medications. Also, although most studies adjust for age, generally the obese HF are slightly younger than 
the leaner patients, as noted in the 4 year younger age in our recent meta-analysis.20 As discussed 
below, adipose tissue in HF may be associated with greater muscular strength, that along with 
cardiorespiratory fitness (CRF) could also improve HF prognosis.27,28   
 
Impact of Frailty/Cachexia in HF 
 
Frailty can be defined as a biological syndrome that is characterized by declining overall function 
and loss of resistance to stressors, which is associated with increased morbidity, mortality, and 
healthcare expenditures, particularly in the elderly, who have a high prevalence of HF.28  A recent study 
indicates that frailty was highly prevalent among community patients with HF, and this predicted a 
significant increase in the risk of hospitalization and emergency department encounters, independent of 
other comorbidities.29   
 
Cachexia is a particularly ominous accompaniment of advanced HF.28  Certainly, unintentional 
weight loss carries an extremely high burden of morbidity and mortality for most medical conditions, 
and the same is true for HF.  Although many studies have suggested a worse prognosis associated with 
weight loss in HF, a limitation of most of these studies is that purposeful weight loss was not 
differentiated from non-purposeful weight loss, and studies generally were not able to account for non-
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purposeful weight loss prior to study entry.5,28  To an extent, overweight and obesity in HF may 
represent the opposite of cachexia, or reverse epidemiology.28,30   
 
Recent studies have suggested that fat loss may precede lean muscle mass loss as cardiac 
cachexia becomes manifest, and fat loss may signal the onset of declining prognosis in HF.28,31  These 
studies have also made a link between cardiac cachexia and RV dysfunction.  Besides preventing weight 
loss, potentially useful strategies for cardiac cachexia in HF are discussed elsewhere.28   
 
Impact of Severe or Class III Obesity 
 
Although an obesity paradox exists for most CVD as well as HF, it is most likely that this mostly 
applies to overweight and mildly obese patients, less so for Class II obesity (BMI 35-40 kg/m2) and 
probably not for more severe, or Class III obesity (BMI ≥ 40 kg/m2).32,33  In CHD, for example, although an 
obesity paradox was noted short-term for all classes of BMI, more severe obesity was associated with 
worse survival during long-term follow-up.34,35  The impact of morbid or Class III obesity in HF prevalence 
and prognosis is most concerning, since recent studies suggest that more severe obesity is increasing 
more so than obesity per se.1,5  Additionally, this level of severe obesity has particularly detrimental 
affects on CV structure and function, and, as discussed previously, markedly increases the prevalence of 
HF.5,7,18  Unlike less severe degrees of obesity, where an obesity paradox generally seems to exist, at 
least in short-term follow-up studies, many studies suggest that Class III obesity is associated with a poor 
HF prognosis.32,33   
 
Impact of Fitness in HF 
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Substantial data indicate that muscular strength and levels of CRF markedly impacts prognosis in 
many CVD patients, including HF.27,36  In fact, low levels of CRF may be one of the strongest risk factors 
for CVD and total mortality.37-39  High levels of CRF, including higher workloads on treadmill stress tests, 
longer 6-minute walking time, and higher peak oxygen consumption (VO2) , are associated with better 
prognosis in most CVD, including CHD and HF.36-41  In addition, Lavie and colleagues42 demonstrated that 
CRF strongly mitigates the impact of adiposity on subsequent prognosis in HF.  In a study of 2,066 
patients with systolic HF, those with a relatively preserved CRF (peak VO2 ≥ 14 cc/kg/min) have a 
favorable prognosis regardless of weight.  In contrast, those with poor CRF (peak VO2 < 14 cc/kg/min), a 
strong obesity paradox was apparent (Figure 4), with the lean HF patients, even after excluding 
underweight patients, with poor CRF having particularly high mortality compared with heavier 
patients.42  These data were recently confirmed in a study from Clark et al.43   
 
These data support physical activity and exercise training to increase levels of CRF to improve 
prognosis in HF patients.36  Although the results of the recent HF: ACTION (Heart Failure: A Controlled 
Trial Investigating Outcomes of Exercise Training) were less impressive than expected, as the exercise 
training only produced a modest 4% average increase in peak VO2,(which was well less than the 10% to 
15% improvements anticipated),44 still this therapy reduced the primary endpoint of all-cause mortality 
in HF hospitalizations by 11% after adjusting for baseline factors.  However, in patients who were more 
compliant with exercise training, greater increases in peak VO2 were associated with 30% reductions in 
mortality and hospitalizations.45  Therefore, recommending exercise training to improve CRF is 
important to improve HF prognosis. Although randomized controlled trials of resistance training on long-
term prognosis are not available in HF, many studies have demonstrated better prognosis associated 
with higher levels of muscular strength, which are also associated with better quality of life.27,28  Thus, it 
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is reasonable  based on current information to include resistance training with aerobic exercise training 
for most patients with HF.   
 
Intentional Weight Loss in HF 
 
Intentional weight loss may be one of the most effective long-term therapies for improving the 
hemodynamics and cardiac structure and functional abnormalities associated with obesity, most of 
which adversely impact HF.5,7 Despite this evidence, however, and considering the previously discussed 
obesity paradox and adverse impact of cardiac cachexia and frailty in HF,5,7,28 the major HF societies 
during the past decade have vastly different recommendations regarding intentional weight loss 
strategies, with none recommending weight loss for the overweight BMI patients.5  Because of the lack 
of definitive large-scale clinical trials on the role of weight loss in HF to make firm guidelines and 
recommendations, the more recent HF guidelines from the American College of Cardiology 
Foundation/American Heart Association do not provide any firm recommendations for intentional 
weight loss in HF, except for the recognition of the particularly poor prognosis present in severe or 
morbid, Class III obesity (BMI ≥ 40 kg/m2).46   
 
Therefore, based on the constellation of data, recommendations for purposeful weight loss, 
including possibly bariatric surgery, for severely obese HF patients, seem sound, and this seems 
reasonable for moderate-severe obesity, with BMI ≥ 35 kg/m2.5,7,9  In less severe obesity and in 
overweight HF patients, although weight loss may improve symptoms and functional class, data on 
major HF morbidity and mortality are lacking.  Therefore, in overweight and mildly obese HF patients, 
prevention of weight gain and improving CRF may be preferable goals.36,47-49 
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Conclusions 
 
Obesity adversely affects hemodynamics and cardiac structure and function, leading to systolic 
and, particularly diastolic LV dysfunction.  Despite this effect, however, many studies suggest an obesity 
paradox, where overweight and mildly obese HF patients have a better prognosis than do normal weight 
patients with HF.  In contrast, underweight HF patients, as well as those with frailty and cardiac 
cachexia, particularly have a poor prognosis.  Although long-term studies of intentional weight loss in HF 
are generally lacking, the constellation of data support intentional weight loss for high risk patients with 
more severe obesity, whereas effects to improve levels of CRF and muscular strength are preferable in 
most HF patients. 
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Figure Legends 
 
1. Proposed pathophysiology of obesity cardiomyopathy. This diagram shows the central 
hemodynamic alterations that result from excessive adipose accumulation in severely-obese 
patients and their subsequent effects on cardiac morphology and ventricular function. Left 
ventricular (LV) hypertrophy in severe obesity may be eccentric or concentric. Factors 
influencing LV remodeling and geometry include severity and duration of obesity, duration and 
severity of adverse LV loading conditions (particularly hypertension) and possibly, 
neurohormonal and metabolic abnormalities such as increased sympathetic nervous system 
tone, activation of the renin–angiotensin–aldosterone system, insulin resistance with 
hyperinsulinemia, leptin resistance with hyperleptinemia, adiponectin deficiency, lipotoxicity 
and lipoapoptosis. These alterations may contribute to the development of LV failure. LV failure, 
facilitated by pulmonary arterial hypertension from sleep apnea/obesity hypoventilation may 
subsequently lead to right ventricular failure.  Reproduced with permission from Alpert MA et 
al.7 
2. Risk of Heart Failure.  Prevalence of heart failure in 5,881 Framingham participants according to 
obesity status.  Reproduced with permission from Kenchaiah et al.17 
3. Meta-analysis of six studies (n-22,807) on impact of body mass index on cardiovascular 
mortality, all-cause mortality, and hospitalizations in heart failure. Reproduced with permission 
from Sharma et al.20 
4. Kaplan-Meier analyses according to body mass index (BMI) with the low cardiorespiratory 
fitness (CRF) group (O2 consumption < 14 mLO2 kg
-1 min-1, log rank 11.7, P=.003) and high CRF 
group (O2 consumption ≥ 14 mLO2 kg
-1 min-1, log rank 1.72, P=.42) on the left and right, 
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respectively.  Reproduced with permission from Lavie et al49 and adapted from data published in 
Lavie et al42. 
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Figure 4 
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Table 1.  Effects of Obesity on Cardiac Performance 
 
A.  Hemodynamics 
1.  Increased blood volume 
2.  Increased stroke volume 
3.  Increased arterial pressure 
4.  Increased LV wall stress 
5.  Pulmonary artery hypertension 
 
B.  Cardiac Structure 
1.   LV concentric remodeling 
2.   LV hypertrophy (eccentric and concentric) 
3.   Left atrial enlargement 
4.   RV hypertrophy 
 
C.  Cardiac Function 
1.   LV diastolic dysfunction 
2.   LV systolic dysfunction 
3.   RV Failure 
  
D.  Inflammation 
1.   Increased C-reactive protein 
2.   Over-expression of tumor necrosis factor 
 
E.  Neurohumoral 
1.   Insulin resistance and hyperinsulinemia 
2.   Leptin insensitivity and hyperleptinemia 
3.   Reduced adiponectin 
4.   Sympathetic nervous system activation 
5.   Activation of renin-angiotensin-aldosterone system 
6.   Overexpression of peroxisome proliferator-activator receptor 
 
F.  Cellular 
1.   Hypertrophy 
2.   Apoptosis 
3.   Fibrosis 
 
 
 
 
LV = left ventricular; RV = right ventricular 
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Table 2.  Potential Reasons for the Obesity Paradox in HF 
 
 
1. Nonpurposeful weight loss. 
2. Greater metabolic reserves 
3. Less cachexia 
4. Protective cytokines 
5. Earlier presentationa 
6. Attenuated response to renin-angiotensin-aldosterone system 
7. Higher blood pressure leading to more cardiac medications 
8. Different cause of HF 
9. Increase muscle mass and muscular strength 
10. Implications related to cardiorespiratory fitness 
 
aCaused by lower atrial natriuretic peptide levels, restrictive lung disease, venous insufficiency, and so 
on.   
 
Reproduced with permission from Lavie CJ et al.5 
